PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Hanna N, Johnson D, Temin S et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35(30), 3484–3515 (2017).
  Medline CASGoogle Scholar
• 2. Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2018).
  Medline CASGoogle Scholar
• 3. European Medicines Agency. Find medicine – Keytruda. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124
  Google Scholar
• 4. European Medicines Agency. Find medicine – Opdivo. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/opdivo
  Google Scholar
• 5. European Medicines Agency. Find medicine – Tecentriq. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq
  Google Scholar
• 6. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016). •• Registrative trial for pembrolizumab monotherapy in first-line therapy for non-small-cell lung cancer (NSCLC) patients with programmed death receptor ligand-1 (PD-L1) expression ≥50%.
  Medline CASGoogle Scholar
• 7. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J. Immunother. Cancer Feb 21 5, 16 (2017).
  MedlineGoogle Scholar
• 8. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018). •• Registrative trial for pembrolizumab plus chemotherapy in first-line therapy for nonsquamous NSCLC patients regardless of PD-L1 expression.
  Medline CASGoogle Scholar
• 9. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018). •• Registrative trial for pembrolizumab plus chemotherapy in first-line therapy for squamous NSCLC patients regardless of PD-L1 expression.
  Medline CASGoogle Scholar
• 10. Barlesi F, Nishio M, Cobo M et al. LBA54IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann. Oncol. 29(Suppl. 8), mdy424.066–mdy424.066 (2018).
  MedlineGoogle Scholar
• 11. Jotte RM, Cappuzzo F, Vynnychenko I et al. IMpower131: primary PFS and safety analysis of a randomized Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J. Clin. Oncol. 36(18 Suppl.), LBA9000–LBA9000 (2018).
  Google Scholar
• 12. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018). •• Registrative trial for atezolizumab plus chemotherapy in first-line therapy for nonsquamous NSCLC patients regardless of PD-L1 expression.
  Medline CASGoogle Scholar
• 13. Socinski MA, Jotte RM, Cappuzzo F et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J. Clin. Oncol. 36(15 Suppl.), 9002–9002 (2018).
  Google Scholar
• 14. Cappuzzo F, Mccleod M, Hussein M et al. LBA53IMpower130: progression-free survival (PFS) and safety analysis from a randomised Phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann. Oncol. 29(Suppl. 8), mdy424.065–mdy424.065 (2018).
  MedlineGoogle Scholar
• 15. Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378(22), 2093–2104 (2018).
  Medline CASGoogle Scholar
• 16. Borghaei H, Hellmann MD, Paz-Ares LG et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227. J. Clin. Oncol. 36(15 Suppl.), 9001–9001 (2018).
  Google Scholar
• 17. Pilotto S, Carbognin L, Rossi A, Tortora G, Bria E. Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: rule or option? Semin. Oncol. 45(3), 176–180 (2018). • Systematic review and meta-analysis of pembrolizumab versus pembrolizumab plus chemotherapy in first-line therapy for NSCLC patients with PD-L1 expression ≥50%.
  MedlineGoogle Scholar
• 18. Carbognin L, Pilotto S, Milella M et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE 10(6), e0130142 (2015).
  MedlineGoogle Scholar
• 19. Pilotto S, Di Maio M, Peretti U et al. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: sensitivity and meta-regression analysis of randomized trials. Crit. Rev. Oncol. Hematol. 90(2), 135–145 (2014).
  MedlineGoogle Scholar
• 20. Hirsch FR, Mcelhinny A, Stanforth D et al. PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J. Thorac. Oncol. 12(2), 208–222 (2017).
  MedlineGoogle Scholar
• 21. Tsao MS, Kerr KM, Kockx M et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase II Project. J. Thorac. Oncol. 13(9), 1302–1311 (2018).
  MedlineGoogle Scholar
• 22. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J. Clin. Oncol. 22(19), 3839–3841 (2004).
  MedlineGoogle Scholar